Immunotherapy has recently shown promise in bone cancer. We have found that while immune modulators Il-6 and Ifn?? contribute to tumour suppression Il-23 promotes the growth of radiation-induced bone cancer. We have generated mouse models of bone cancer to investigate tumour growth and immune surveillance in immune competent mice with an overall aim of identifying therapeutic targets in this disease.
Characterisation Of Two Novel Markers Of Osteosarcoma Metastasis As Potential Therapeutic Targets
Funder
National Health and Medical Research Council
Funding Amount
$624,500.00
Summary
Osteosarcoma (OS) is the most common bone tumour in children and adolescents. In spite of aggressive chemotherapy, OS tumours that metastasise to the lungs result in dismal long-term survivals of only 10-20%. For these patients, new treatment options are desperately needed. In this proposal we show compelling data identifying two new markers of OS metastasis. This research aims to validate the suitability of these novel markers as therapeutic targets to prevent OS metastasis.
Control Of Gastrointestinal Tumour Progression By Therapeutic Interference With Myeloid Derived Cells
Funder
National Health and Medical Research Council
Funding Amount
$758,678.00
Summary
Cancers of the stomach and the colon are a major health burden. Despite our increased molecular understanding of the mutation that cause these cancers our treatment options are very limited. Here we will use sophisticated and validated mouse models for these cancers to establish how blood-borne cells contribute to the growth and spreading of these cancer. We will use these models to establish highly effective treatment combinations of therapeutic agents that are already undergoing preclinical te ....Cancers of the stomach and the colon are a major health burden. Despite our increased molecular understanding of the mutation that cause these cancers our treatment options are very limited. Here we will use sophisticated and validated mouse models for these cancers to establish how blood-borne cells contribute to the growth and spreading of these cancer. We will use these models to establish highly effective treatment combinations of therapeutic agents that are already undergoing preclinical testing.Read moreRead less
Colorectal cancer (CRC) is one of the most common causes of cancer-associated death in the world. We aim to understand why some CRC patients stop responding to EGFR therapy. In particular, we will study small molecules called cytokines that are produced by the tumour microenvironment and determine if the inhibition of these cytokines can over-come the acquired resistance to therapy. Our goal is to identify new ways to improve the current treatment options for CRC patients.